Recent Updates
Recently added Catalysts
KYMR Positive Sentiment Score: 70/100

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Thursday, January 30, 2025 1 min read
Key Takeaway: Kymera Therapeutics, Inc. has announced its participation in two upcoming investor conferences. The first is the Guggenheim SMID Cap Biotechnology Conference in New York on February 6, followed by the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11. Both events will include fireside chats, and live webcasts will be available for investors. This involvement underscores Kymera's commitment to engaging with the investment community and promoting their innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in prominent investor conferences signals growth potential.
  • Webcasts provide transparency and accessibility for investors.
  • Focus on innovative degrader medicines attracts attention in biotech.

Full Press Release Details

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and
Oppenheimer 35th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Investor and Media Contact:
Vice President, Investor Relations
investors@kymeratx.com

Tags

Targeted Protein Degradation

Frequently Asked Questions

What events will Kymera Therapeutics attend?

Kymera Therapeutics will participate in the Guggenheim SMID Cap Biotechnology Conference and the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

When is the Guggenheim Biotechnology Conference?

The Guggenheim SMID Cap Biotechnology Conference is on February 6 at 10:00 a.m. ET.

Where can I find Kymera's presentation webcasts?

Live webcasts can be accessed in the Investors section of Kymera’s website.

When will replays of the webcasts be available?

Replays of the webcasts will be available for viewing after the events.

What type of medicines does Kymera develop?

Kymera develops oral small molecule degrader medicines for immunological diseases.

Tags: KYMR Viatris Investor Conferences Healthcare Kymera Therapeutics investor conferences biopharmaceuticals innovation
Last updated: Jan 30, 2025